Candel Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Candel Therapeutics, Inc. on June 23, 2026. The record date for the meeting was April 24, 2026, with 73,270,239 outstanding shares of voting common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1 (Election of Directors): Stockholders elected four Class II directors to serve until the 2029 annual meeting. The nominees were Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. All nominees were elected.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Breakdown
| Director Nominee | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Edward J. Benz, Jr., M.D. | 24,897,348 | 6,796,622 | 22,175,525 |
| Paul B. Manning | 31,591,618 | 102,352 | 22,175,525 |
| Maha Radhakrishnan, M.D. | 31,047,706 | 646,264 | 22,175,525 |
| Paul Peter Tak, M.D., Ph.D., FMedSci | 31,414,668 | 279,302 | 22,175,525 |
Proposal 2 Voting Results: For: 53,543,020; Against: 238,508; Abstain: 87,967.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Edward J. Benz, Jr., Paul B. Manning, Maha Radhakrishnan, and Paul Peter Tak) extending to the 2029 annual meeting.
- Confirm the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026.
- Note the significant number of broker non-votes (22,175,525) recorded for the director elections, which may indicate shares held in street name where brokers lacked discretionary voting power.
- Review the Definitive Proxy Statement filed on April 29, 2026, for detailed biographies of directors and further context on the proposals.